VIKING THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.2 USD | +0.36% |
|
+5.86% | +330.95% |
| 05-06 | Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing | MT |
| 05-03 | Wall St set to open sharply higher on soft jobs data | RE |
Presentation Operator MessageOperator (Operator)Welcome to the Viking Therapeutics 2022 Second...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
Calendar
2024-05-21
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
79.91
USD
Average target price
108.4
USD
Spread / Average Target
+35.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +330.95% | 8.81B | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- VKTX Stock
- News Viking Therapeutics, Inc.
- Transcript : Viking Therapeutics, Inc., Q2 2022 Earnings Call, Jul 27, 2022